Pioneers in Medical Cannabis Care, since Ireland's first MCAP approval.

Oleo Technologies is one of Ireland's HPRA-authorised suppliers under the Medical Cannabis Access Programme. We import Bedrocan-grade product, manufacture the Oleo Panacea inhaler, and run the OleoCare platform that connects patients and prescribers.

HPRA-authorised MCAP supplier Irish Government MCAP register

Richard Creagh

Co-Founder, Oleo Technologies

"We started Oleo because Irish patients were being turned away by a system that couldn't supply them. Six years on, we're the supplier they get sent to."

Read Richard's full story →

For Patients

Three conditions covered today. More may follow the April 2026 review.

The Medical Cannabis Access Programme covers three indications. If you have one of them and you've tried conventional treatment without relief, talk to your consultant about an MCAP referral.

MS Spasticity

For multiple sclerosis patients with spasticity that hasn't responded to conventional medication. Reviewed by named consultant neurologists.

Learn more →

Chemo-Induced Nausea

For cancer patients with severe chemotherapy-induced nausea and vomiting that hasn't responded to standard antiemetics.

Learn more →

Refractory Epilepsy

For patients with severe, treatment-resistant epilepsy. Particularly relevant for children and adolescents whose seizures haven't responded to standard antiepileptic drugs.

Learn more →

Our Products

Devices and platforms designed around the patient and the prescriber.

[Real Oleo Panacea product photograph - replaces stock]

Oleo Panacea

A precision dry-herb vaporiser inhaler designed for medical cannabis flower. Built for adherence, designed for the unique requirements of MCAP-prescribed treatment.

Precise dose control
Pairs with the OleoCare app for adherence tracking
Built for medical use, not recreational

Regulatory status [TO CONFIRM: CE-marked Class IIa under MDR (EU) 2017/745]

OleoCare

The free patient and prescriber platform. Patients log dosages, symptoms, and side effects. Prescribers monitor in real time and adjust treatment with full data visibility.

Symptom and adherence tracking
Treatment reminders and dose history
Real-time prescriber dashboard
GDPR-compliant Article 9 data handling

[Real OleoCare app screenshots - patient + prescriber views]

Two Audiences

Find what you need, fast.

Patients researching options and prescribers preparing applications need different things. We've split the site so you don't have to scroll past content that isn't relevant.

For Patients + Caregivers

Understand your options under MCAP

Eligibility criteria, application process, what to expect, costs and reimbursement, and the conditions currently covered. Plain English, regulator-aligned.

Start with the MCAP guide →

For Healthcare Professionals

Resources for MCAP prescribers

The prescriber handbook. Step-by-step licence-application guide. CPD modules on cannabis-prescribing in Ireland. The OleoCare prescriber portal.

Open the prescriber resource library →

The Programme

What the Medical Cannabis Access Programme covers.

MCAP is the Irish government's reimbursement scheme for medical cannabis. Patients with MS spasticity, severe chemotherapy-induced nausea, or treatment-resistant epilepsy can be prescribed cannabis-based medicines through MCAP. Costs are reimbursed by the HSE.

A formal review of MCAP, led by Professor Shane Allwright at Trinity College Dublin, is currently underway. The review is examining eligibility, supplier authorisation, and the patient pathway. Outcomes are expected to shape the programme's next phase.

Read the MCAP guide →

2021

Year Oleo was added to the MCAP register

Conditions covered today

HPRA

Authorised by Ireland's pharmaceutical regulator

2026

MCAP scheme review currently underway